Natalie Goedeker, CPNP, on Supporting Gene Therapy’s Ascendance in Muscular Dystrophies

The nurse practitioner from Washington University in St. Louis discussed the practical considerations in gene therapy track she chaired at the 2023 MDA Conference.

"Duchenne muscular dystrophy was denied being added to the recommended newborn screening panel. ...the community has to focus on getting data [in this disease] in the coming years. Probably it will require some sort of clinical trial, but we definitely need data in young children showing that it makes a difference, treating them that their diagnosis from birth will make a difference versus a symptomatic diagnosis in outcomes once we do have a good treatment.”

One track, chaired by Natalie Goedeker, CPNP, pediatric neurology, at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, March 19-22, in Dallas, Texas was the Practical Considerations in Gene Therapy Track that discussed unmet research, education, and infrastructure needs that must be addressed across rare dystrophies such as spinal muscular atrophy and Duchenne muscular dystrophy (DMD).

CGTLive spoke with Goedeker to learn more about the conversations that arose during the practical considerations in gene therapy track. She discussed the importance of having rare diseases like DMD on newborn screening panels and data that will need to come out in the near future to support that implementation. She also touched on positive patient and physician perspectives on accelerated approval shared during one of the sessions on the track at the conference.

Read more coverage of the 2023 MDA Conference here.

Practical Considerations in Gene Therapy Track. Presented at: 2023 MDA Conference, March 19-22; Dallas, Texas.
Related Videos
Jennifer Kwon, PhD, on Reducing LDL Cholesterol in NHPs With Epigenome Editing
Olivier Danos, PhD, on Refining and Specifying AAV Gene Therapy
Paul Harmatz, MD, on Reducing GAGs in MPS Type 2 With RGX-121 Gene Therapy
Francesca Barone, MD, PhD, on Positive Biomarker, Overall Survival Data With CAN-3110 in High-Grade Glioma
Sung-Yun Pai, MD, on High T-Cell Reconstitution in X-SCID With Lentiviral Gene Therapy
Related Content
© 2023 MJH Life Sciences

All rights reserved.